Zimmer Biomet (ZBH) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with expressions of gratitude to employees and shareholders, emphasizing the company's transformation and ongoing strategic priorities for 2026.

• Agenda included a business update, formal business proceedings, and a Q&A session with shareholders.

Strategic initiatives and plans

• Continued focus on people and culture, operational excellence, and innovation/diversification as core priorities.

• Emphasis on specialized U.S. sales channels and new go-to-market strategies to boost competitiveness in high-growth segments like robotics and ASCs.

• Innovation pipeline has doubled, with new products such as the Oxford Partial Cementless Knee and Monogram AI-driven robotic system expected to launch in 2027.

• Planned completion of U.S. commercial changes by end of 2027 to coincide with Monogram launch and dedicated robotics sales team.

Financial performance review

• Disciplined cost management supports earnings per share growth and ongoing investment.

• Free cash flow expected to grow in the upper single-digit to double-digit range.

• Capital allocation prioritizes share repurchases and dividends over M&A, with up to $1 billion in share repurchases planned for the year.